Timing is everything: new trial seeks to boost lung cancer treatment by rescheduling immunotherapy
NCT ID NCT07190027
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This clinical trial is testing whether giving immunotherapy a few days after chemotherapy, instead of on the same day, can improve outcomes for people with advanced non-small cell lung cancer. The study will enroll 246 adults and compare three different timing schedules, including a personalized approach based on daily immune monitoring. The goal is to see if adjusting the timing can shrink tumors more effectively and delay disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-1 inhibitor (e.g., sintilimab, pembrolizumab, camrelizumab) combined with platinum-based chemotherapy
What this could lead to
If successful, this could show that timing immunotherapy a few days after chemotherapy improves tumor shrinkage and delays progression in advanced lung cancer.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small sample, so results may not be conclusive. The personalized timing approach is complex and may not work better than standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••